Jie Yang

7PUBLICATIONS
76CO-AUTHORS
Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsImmunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jan 16, 2026
Fine-tuning BACH2 dosage balances stemness and effector function to enhance antitumor T cell therapy.

Alberto G Conti, Alexander C Evans, Teresa von Linde

|Mar 05, 2025
Aspirin prevents metastasis by limiting platelet TXA2 suppression of T cell immunity.

Jie Yang, Yumi Yamashita-Kanemaru, Benjamin I Morris

|Jul 12, 2024
IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy.

Charlotte J Imianowski, Paula Kuo, Sarah K Whiteside

|Dec 15, 2023
Acquisition of suppressive function by conventional T cells limits antitumor immunity upon Treg depletion.

Sarah K Whiteside, Francis M Grant, Giorgia Alvisi

|Dec 02, 2022
IL-2 is inactivated by the acidic pH environment of tumors enabling engineering of a pH-selective mutein.

Silvia Gaggero, Jonathan Martinez-Fabregas, Adeline Cozzani

|Sep 30, 2022
BACH2 restricts NK cell maturation and function, limiting immunity to cancer metastasis.

Charlotte J Imianowski, Sarah K Whiteside, Teresa Lozano

Pageof 2

Frequent Collaborators

6 joint publications

Rahul Roychoudhuri

5 joint publications

Charlotte J Imianowski

5 joint publications

Alexander C Evans

4 joint publications

Klaus Okkenhaug